VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis

Annals of Clinical and Translational Neurology

Volumn 1, Issue 5, 2014, Pages 329-339

  Avidan, Nili ^a   Le Panse, Rozen ^b   Harbo, Hanne F ^c,d   Bernasconi, Pia ^e   Poulas, Konstantinos ^f   Ginzburg, Elizabeta ^a   Cavalcante, Paola ^e   Colleoni, Lara ^e   Baggi, Fulvio ^e   Antozzi, Carlo ^e   Truffault, Frédérique ^b   Horn Saban, Shirley ^g   Pöschel, Simone ^h,i   Zagoriti, Zoi ^f   Maniaol, Angelina ^c   Lie, Benedicte A ^c,d   Bernard, Isabelle ^j,k   Saoudi, Abdelhadi ^j,k   Illes, Zsolt ^l,m   Casasnovas Pons, Carlos ⁿ   Melms, Arthur ^h,i   Tzartos, Socrates ^f,o   Willcox, Nicholas ^p   Kostera Pruszczyk, Anna ^q   Tallaksen, Chantal ^c,d   Mantegazza, Renato ^e   Berrih Aknin, Sonia ^b   Miller, Ariel ^a,r   more..

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Sorbonne Université   (France)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f UNIVERSITY OF PATRAS   (Greece)

^g WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^j INSERM   (France)

^k CNRS   (France)

^l UNIVERSITY OF PÉCS   (Hungary)

^m ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁿ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^o HELLENIC PASTEUR INSTITUTE   (Greece)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q MEDICAL UNIVERSITY OF WARSAW   (Poland)

^r CARMEL MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

A KINASE ANCHOR PROTEIN 12; B CELL ACTIVATING FACTOR; CD86 ANTIGEN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VAV 1 GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ADOLESCENT; ADULT; ARTICLE; B CELL ACTIVATING FACTOR GENE; B LYMPHOCYTE ACTIVATION; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; VAV 1 GUANINE NUCLEOTIDE EXCHANGE FACTOR GENE;

EID: 84994857768     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.51     Document Type: Article

References (52)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475–490.
2. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–1059.
3. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 2010;10:46.
4. Janer M, Cowland A, Picard J, et al. A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum Immunol 1999;60:909–917.
5. Gregersen PK, Kosoy R, Lee AT, et al. Risk for myasthenia gravis maps to a (151) Pro–>Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol 2012;72:927–935.
6. Weiss JM, Cufi P, Bismuth J, et al. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology 2013;218:373–381.
7. Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 2011;121:121–129.
8. Ramanujam R, Pirskanen R, Ramanujam S, et al. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Hum Genet 2011;14:129–136.
9. Avidan N, Le Panse R, Berrih-Aknin S, et al. Genetic basis of myasthenia gravis – a comprehensive review. J Autoimmun 2013; doi: 10.1016/j.jaut.2013.12.001 [Epub ahead of print]
10. Vandiedonck C, Beaurain G, Giraud M, et al. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci USA 2004;101:15464–15469.
11. Candore G, Lio D, Colonna Romano G, et al. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 2002;1:29–35.
12. Maniaol AH, Elsais A, Lorentzen AR, et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012;7:e36603.
13. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448:934–937.
14. Visscher PM, Brown MA, McCarthy MI, et al. Five years of GWAS discovery. Am J Hum Genet 2012;90:7–24.
15. Nicolle MW. Myasthenia gravis. Neurologist 2002;8:2–21.
16. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217–1223.
17. Chan M, Chan MW, Loh TW, et al. Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting. J Mol Diagn 2011;13:305–312.
18. Fan JB, Gunderson KL, Bibikova M, et al. Illumina universal bead arrays. Methods Enzymol 2006;410:57–73.
19. Ritchie ME, Liu R, Carvalho BS, et al. Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips. BMC Bioinformatics 2011;12:68.
20. Tian C, Gregersen PK, Seldin MF. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008;17:R143–R150.
21. Nelis M, Esko T, Magi R, et al. Genetic structure of Europeans: a view from the North-East. PLoS One 2009;4:e5472.
22. Elahi MM, Asotra K, Matata BM, et al. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta 2009;1792:163–172.
23. Gordon T, Grove B, Loftus JC, et al. Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Invest 1992;90:992–999.
24. Nauert JB, Klauck TM, Langeberg LK, et al. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol 1997;7:52–62.
25. Gelman IH. Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes Cancer 2010;1:1147–1156.
26. Lisak RP, Ragheb S. The role of B cell-activating factor in autoimmune myasthenia gravis. Ann N Y Acad Sci 2012;1274:60–67.
27. Kim JY, Yang Y, Moon JS, et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008;199:151–154.
28. Berrih-Aknin S, Ragheb S, Le Panse R, et al. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 2013;12:885–889.
29. Dalakas MC. Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 2013;12:936–941.
30. Tuosto L. NF-kappaB family of transcription factors: biochemical players of CD28 co-stimulation. Immunol Lett 2011;135:1–9.
31. Tybulewicz VL, Ardouin L, Prisco A, et al. Vav1: a key signal transducer downstream of the TCR. Immunol Rev 2003;192:42–52.
32. Colacios C, Casemayou A, Dejean AS, et al. The p.Arg63Trp polymorphism controls Vav1 functions and Foxp3 regulatory T cell development. J Exp Med 2011;208:2183–2191.
33. 2-induced IgE and autoimmunity by a 117-kb interval on rat chromosome 9 through CD4 CD45RC(high) T cells. Genes Immun 2013;14:258–267.
34. Jagodic M, Colacios C, Nohra R, et al. A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. Sci Transl Med 2009;1:10–21.
35. Rose AM, Bell LC. Epistasis and immunity: the role of genetic interactions in autoimmune diseases. Immunology 2012;137:131–138.
36. Sun SC, Chang JH, Jin J. Regulation of nuclear factor-kappaB in autoimmunity. Trends Immunol 2013;34:282–289.
37. Oshima S, Turer EE, Callahan JA, et al. ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature 2009;457:906–909.
38. Wagner S, Carpentier I, Rogov V, et al. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008;27:3739–3745.
39. Ramirez VP, Gurevich I, Aneskievich BJ. Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev 2012;23:109–118.
40. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997;34:391–399.
41. Toonen EJ, Barrera P, Fransen J, et al. Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Res Ther 2012;14:R264.
42. Liu ZH, Ding YL, Xiu LC, et al. A meta-analysis of the association between TNF-alpha -308G>A polymorphism and type 2 diabetes mellitus in Han Chinese population. PLoS One 2013;8:e59421.
43. Skeie GO, Pandey JP, Aarli JA, et al. TNFA and TNFB polymorphisms in myasthenia gravis. Arch Neurol 1999;56:457–461.
44. Zelano G, Lino MM, Evoli A, et al. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis. Eur J Immunogenet 1998;25:403–408.
45. Duan RS, Wang HB, Yang JS, et al. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 2002;19:169–174.
46. Wang HB, Li H, Shi FD, et al. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int Immunol 2000;12:1381–1388.
47. Yan M, Xia C, Cheng C, et al. The role of TNF-alpha and its receptors in the production of Src-suppressed C kinase substrate by rat primary type-2 astrocytes. Brain Res 2007;1184:28–37.
48. Gradolatto A, Nazzal D, Foti M, et al. Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17. Ann N Y Acad Sci 2012;1274:40–47.
49. Gradolatto A, Nazzal D, Truffault F, et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-alpha. J Autoimmun 2014; doi: 10.1016/j.jaut.2013.12.015 [Epub ahead of print]
50. Yurkovetskiy L, Burrows M, Khan AA, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity 2013;39:400–412.
51. Bermejo-Alvarez P, Rizos D, Lonergan P, et al. Transcriptional sexual dimorphism during preimplantation embryo development and its consequences for developmental competence and adult health and disease. Reproduction 2011;141:563–570.
52. Kaur M, Schmeier S, MacPherson CR, et al. Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravis. BMC Genomics 2008;9:481.